NEW YORK (GenomeWeb News) – Mizuho Securities has initiated coverage of Fluidigm and BG Medicine, placing a Buy rating on both firms.

For Fluidigm, Mizuho analyst Peter Lawson has placed a $17 price target on the firm's stock, a roughly 11 percent premium to Thursday's closing price of $15.28.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Jay Shendure and his colleagues have developed a new method to more comprehensively identify human cell types, the NY Times reports.

Researchers in the UK and Japan have shown that infertility in mice with three sex chromosomes can be overcome, according to the Guardian.

China is embracing preimplantation genetic diagnosis, Nature News reports. 

In PLOS this week: host genetic factors associated with cervical neoplasia progression, population patterns for an ancient flowering rainforest plant, and more.